Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Creative Biolabs Launched a Brand New Carbohydrate Based Conjugation Service

Creative Biolabs
Posted on: 04 Jan 18

Recently, Creative Biolabs, a professional contract research organization in the frontier of antibody-drug conjugate, launched their brand new carbohydrate based conjugation service, intending to develop customized ADCs that fit clients' requirements, timeline, and R&D budget.


With a sufficient distant from the variable region that regulates antigen interaction, the carbohydrate moiety on an antibody is located at the hinge region of the Fc domain. So conjugation involving carbohydrate moiety can’t impair the antigen binding affinity and may potentially serves as an excellent alternative for site-specific antibody drug conjugate (ADC) generation.


“Our strategy provides an alternative for carbohydrate based conjugation by glycol-engineering of the antibody during its expression. It helps to generate antibodies with thiol-functionalized glycans that can serve as “orthogonal handles" for the attachment of drugs or drug-linker sets containing, for instance, maleimide conjugation functional groups. " a scientist from Creative Biolabs said that.


“This service proves to be an efficient approach for the development of site-specific ADCs, which is suitable for the conjugation to glycosylated full length IgG. And it requires no antibody protein sequence modification or engineering. So I believe that it will be your great assistant for you in ADC development. "


As an international cooperation, Creative Biolabs is committed to utilizing various new technologies to provide comprehensive antibody modification and conjugation services to help our clients with various ADC development projects


About Creative Biolabs

Established in 2004, Creative Biolabs is highly specialized in advanced antibody biochemistry and engineering. With more than a decade of exploration and expansion, our current research and service capacity covers the entire new drug discovery and development pipeline, ranging from early discovery, preclinical evaluations, cGMP manufacturing, to clinical trails. As an international cooperation, we have established offices all around the globe with more than 200 well-trained full-time scientists and technicians, who work closely with our customers and research partners to develop new medicines for a better, healthier world. 


Editor's Details

Bella Smith

Last updated on: 04/01/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.